Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...
Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...
Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...
TipRanks on MSN
Recursion Pharmaceuticals: Q3 2025 Financial Highlights
Recursion Pharmaceuticals, Inc ( ($RXRX) ) has released its Q3 earnings. Here is a breakdown of the information Recursion Pharmaceuticals, Inc ...
Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
TipRanks on MSN
Recursion Pharmaceuticals Announces New CEO Appointment
Recursion Pharmaceuticals ( ($RXRX) ) has provided an update. Recursion Pharmaceuticals announced significant leadership changes effective January ...
Java Development Kit (JDK) 26, a planned update to standard Java due March 17, 2026, has gathered nine features so far. The latest slated for the release include ahead-of-time object caching, an ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results